Kiadis Pharma « Terug naar discussie overzicht

Kiadis Pharma januari 2018.

1.753 Posts, Pagina: « 1 2 3 4 5 6 ... 12 13 14 15 16 17 18 19 20 21 22 ... 84 85 86 87 88 » | Laatste

Omlaag ↓

Koro 13 januari 2018 16:30

Ik denkt dat ze veel eerder geld nodig hebben!

**Productiefaciliteit in Amsterdam. Het biotechnologiebedrijf krijgt daardoor ook de beschikking over laboratoria voor ontwikkeling en kwaliteitscontrole en kantoorruimte voor het hoofdkantoor.
Kiadis geeft aan dat de huur geen invloed heeft op de huidige contracten met producenten. Het bedrijf maakt zich op voor de Europese lancering van zijn celtherapie-oplossing voor beenmergtransplantaties in 2019.

Dit kost echt klauwen met geld!

Koro 13 januari 2018 16:32

Over speculeren gesproken !!:-) waar heb jij deze informatie gevonden?

quote:
regenboog schreef op 13 januari 2018 15:22:
Kiadis Pharma wordt waarschijnlijk in de eerste helft
van 2018 overgenomen.
Men is nu al bezig de lijnen uit te zetten.
De koers blijft voorlopig rond de €.8,00
Straks een bieding op de aandelen van rond €.15,00 p/a.
Daarna een tweede bod van rond de €.20,00 per aandeel.
Met het management wordt een gouden deal gesloten.
Ook de institutionele beleggers ,die momenteel ruim 60% van de aandelen bezitten, gaan akkoord. Met enkelen is al gesproken.
Succes verder , ik ben hier voorlopig weg.
Alle gespeculeer verder op dit forum van anderen heeft geen enkele zin.
A waste of time!!

[verwijderd] 13 januari 2018 17:50

quote:
Koro schreef op 13 januari 2018 16:32:
Over speculeren gesproken !!:-) waar heb jij deze informatie gevonden?

[...]

Deze zat goed verstopt in zijn linkerduim.

[verwijderd] 13 januari 2018 17:55

Daar is ie weer, het donderwolkje dat met zijn mening iedereen probeert te onderdrukken. Iedereen is vrij om zijn eigen mening hier neer te schrijven, toch? Waarom ben je anders op een forum?
Ajs je geen respect toont voor andere meningen heb je hier niets te zoeken.

Goedekans 14 januari 2018 00:51

quote:
Nuchtere Belg schreef op 13 januari 2018 17:55:
Daar is ie weer, het donderwolkje dat met zijn mening iedereen probeert te onderdrukken. Iedereen is vrij om zijn eigen mening hier neer te schrijven, toch? Waarom ben je anders op een forum?
Ajs je geen respect toont voor andere meningen heb je hier niets te zoeken.

Daar is ie weer de "fijne" Belg!!
Kiadis wordt in het eerste kwartaal verkocht!!
Graag een goed onderbouwde mening. :-)

www.youtube.com/watch?v=DdCUnMVJdc0&a...

Ik heb hier niets meer te zoeken. Geweldig!!

Ontop1 14 januari 2018 08:24

quote:
Biobert schreef op 8 januari 2018 21:59:
Zojuist heb ik Novo Nordisk attent gemaakt op Kiadis als interesante partner in plaats van Ablynx, die niet wil. Eens kijken wat voor koersreactie dit geeft morgen.

Ablynx is minimaal 55 euro waard met een opwaarts potentieel dan ga je die tent toch niet verkopen
CAPLA is al 40 waard en dan de rest van de pijplijn zit ook nog veel waarde in.
Denk aan het RSV ALX0171

[verwijderd] 14 januari 2018 10:17

quote:
regenboog schreef op 14 januari 2018 00:51:
[...]

Daar is ie weer de "fijne" Belg!!
Kiadis wordt in het eerste kwartaal verkocht!!
Graag een goed onderbouwde mening. :-)

www.youtube.com/watch?v=DdCUnMVJdc0&a...

Ik heb hier niets meer te zoeken. Geweldig!!

Onderbouw eerst zelf je stelling maar eens. Dit is louter speculatief en als je het mij vraagt wachten de geinteresserde partijen liever nog wat af tot er meer resultaten komen van de lopende test-fases en de goedkeuring door het FDA en Europa.
De uiteindelijke beurswaarde van Kiadis zal bepaald worden door het potentieel van ATIR101 & 2 en niet door de huidige koers

Windkracht 15 januari 2018 10:01

Toch al weer een behoorlijk volume het eerste uur en de aantallen in zowel de bied als de laat zijn erg hoog....

Windkracht 15 januari 2018 10:16

Wat een schitterend verhaal. Wat een life-changing therapie kan CAR-T toch zijn....

www.mdanderson.org/publications/cance...

January 10, 2018
Non-Hodgkin’s lymphoma survivor: A CAR-T cell clinical trial gave me my life back
BY EMILY DUMLER
Before I was on a clinical trial, I felt sorry for patients participating in them. I considered clinical trials a last-ditch effort, and felt they marked a really low point in someone’s life.

So, when I was faced with the possibility of being on one myself, my reaction wasn’t at all what I expected. I felt grateful just to have another option — a really viable one that my doctors were excited about. And for the first time in a long time, I actually felt hopeful.

The long road that led me to MD Anderson

By the time I got to MD Anderson, I had already been through the wringer. I’d had my spleen removed, received every drug known to increase platelet counts, and spent 43 days in a local hospital before I finally received the correct diagnosis — diffuse, large B-cell lymphoma (a type of non-Hodgkin’s lymphoma) — in August 2013.

My treatment in Kansas City included six courses of “R-CHOP” chemotherapy. They appeared to work at first. But seven months later, scans revealed that the cancer had either returned or never really been gone to begin with. I started preparing for an autologous stem cell transplant, in which my own cells would be used to rescue my immune system after high-dose chemotherapy.

But when the high-dose chemo failed, I had to consider the next-best option: an allogenic stem cell transplant, which uses stem cells from a donor. My husband and I weren’t ready to face the additional risks and side effects that come with an allogeneic transplant, so we sought a second opinion at MD Anderson.

Even though it’s two states and 14 hours away, MD Anderson is the top cancer hospital in the country, so the choice seemed pretty obvious. And once we knew that I had lymphoma, we also knew we wanted a hospital that focused exclusively on cancer.

How I found hope twice at MD Anderson

At MD Anderson, Dr. Frederick Hagemeister confirmed my diagnosis, but he also recommended a new treatment plan — one that would still allow me to use my own stem cells. I had an autologous stem cell transplant at MD Anderson in January 2015. Unfortunately, it wasn’t successful.

I cannot tell you how terrifying it was to learn that the cancer was still there and I had no good options left. My local doctor said my only chance at a cure was CAR-T cell immunotherapy. That’s where doctors harvest your T-cells, then reengineer them by adding a receptor that binds to cancer cells so that they can recognize, attack and kill it. The cells are infused back into your body through an IV.

At the time, CAR-T cell therapy had been used mainly for leukemia, but multicenter clinical trials were starting to be talked about for lymphoma. MD Anderson was about to launch its own CAR-T cell lymphoma clinical trial, and Dr. Sattva Neelapu had just one spot left. I was excited to learn that I qualified.

My CAR-T cell infusion

I had my CAR-T cell infusion at MD Anderson on July 13, 2015. Since I was only the second patient at MD Anderson and the third one in the world to receive CAR-T cells to treat non-Hodgkin’s lymphoma on this clinical trial, there were a lot of clinicians in the room, watching.

The infusion normally only takes a few minutes, but my sinuses started to close up almost immediately, like an allergic reaction. I worried my throat would close up, too, so they paused the infusion and gave me an antihistamine through an IV. We had only a very short timeframe — about 30 minutes — to complete the infusion, so once it was clear that the antihistamine was helping, we continued.

My scariest CAR-T cell therapy side effect

I stayed in the hospital for nine days. The worst side effect I experienced was probably “cytokine release syndrome.” It’s like a really bad flu, because your body — with the help of those reengineered cells — is working so hard to fight the cancer. One of the scariest parts is that sometimes you become unable to answer even the simplest questions, like, “What’s your name?” or “What color is this?”

For me, the neurological side effects appeared on the fourth or fifth day after the infusion. I needed a CT scan, and a nurse was telling me to swing my legs off the bed so she could help me into a wheelchair. I could hear and understand her, but I couldn’t make my body respond. Later, a doctor pointed to a picture of my son and asked me who he was. I said his name was “Spanish.” (Actually, it’s “Hudson.”)

My doctors used a rheumatoid arthritis drug to reverse the syndrome’s effects. They only lasted about 24 hours, but it was still really scary for me to experience and for my husband to watch. The doctors said that everything should eventually return to normal, but with me being such an early user of CAR-T cell therapy, they couldn’t know for sure.

Happily, by the time I got out of the hospital, I felt a lot better, and by the time I went back for my scans in August, I was feeling really good. But the best news of all is that I was also in complete remission, and I have stayed that way for two-and-a-half years.

My legacy: saving others people’s lives

CAR-T cell therapy has since been approved by the FDA for treating lymphoma. But knowing that I was a trailblazer in this area makes me feel so proud. Clinical trials are the future of medicine. And they really are how new treatments become available.

Seeing how far CAR-T cell therapy has come — and knowing that my help in getting it approved might be saving other people’s lives — is amazing. I was so sick for so long, that at some point, I felt like cancer had become my life. Cancer consumes you, whether you want it to or not, so getting to return to work full time and attend all of my kids’ games and practices again has been wonderful.

I didn’t think my life would ever be normal again. It’s been really awesome to realize that it is.

Windkracht 15 januari 2018 10:28

www.bioinformant.com/pharma-investing...

Is the CAR-T Craze Driving Pharma Investment into Cell Therapy Companies?

January 13, 2018 By Cade Hildreth (CEO) 1 Comment

Without a doubt, the cell therapy industry is coming of age. In addition to growing numbers of cell therapy clinical trials, numerous cell therapy products have been approved by regulatory agencies worldwide and 150+ cell therapy companies are competing within the global marketplace. These metrics are extremely important, because they indicate that the market for cell therapy products is expanding.

However, one of the most telling trends within the industry is a growing interest among “big pharma” in cell therapy companies.

At its core, this is a strategic way for pharmaceutical companies to diversity their product development pipeline.

At first the trend was subtle, but the tide has swelled as CAR-T therapies have reached the marketplace and created a “craze” for promising CAR-T product candidates.

Gilead Sciences received approval for Yescarta in October 2017 as a result of its Kite Pharma acquisition for $11.9B. More recently, Johnson & Johnson agreed to pay $350 million to partner with Chinese firm Nanjing Legend Biotech after the company released promising CAR-T data at the ASCO annual meeting. Gilead is also acquiring Cell Design Labs, a biotech company developing novel CAR-T and T cell receptor therapies in a deal valued at up to $567 million.

Other deal-making in this space includes bluebird bio’s broad strategic collaboration with Celgene Corporation to commercialize CAR T-cell programs and Pfizer’s CAR-T collaboration with Cellectis that was accompanied by $80 million upfront payment and up to $185 million per product with royalties.

Additionally, Bellicum Pharmaceuticals and Agensys, an affiliate of Astellas Pharma, have a global license agreement that allows Bellicum to commercialize adoptive cell therapies, including CAR-T cells, for tumors expressing Prostate Stem Cell Antigen (PSCA).

Of course, there have also been more than a dozen CAR-T deals between pharmaceutical companies and academic institutions, with the best known being the partnership between Novartis and the University of Pennsylvania (UPenn). In August 2017, the U.S. FDA announced that Kymriah™ would be the first CAR-T cell therapy to be approved in the U.S., an accomplishment that resulted from a 5-year collaboration between UPenn and Novartis.

However, this deal-making isn’t limited to CAR-T cell therapy deals. A full review of “big pharma” investment into cell therapy companies is explored below.

Pharma Industry Accelerating Investment into Cell Therapy Companies
Key investments by the pharmaceutical sector into cell therapy companies are highlighted below:

Takeda Pharmaceutical Company announced its intent to acquire TiGenix for €520m in January 2018. TiGenix is exploring ant-inflammatory properties of allogeneic stem cells (lead product, Cx601).
Gilead announced December 2017 that it is acquiring Cell Design Labs, a biotech company developing novel CAR-T and T cell receptor therapies in a deal valued at up to $567 million.
Johnson & Johnson is paying $350 million upfront to partner with Chinese firm Nanjing Legend Biotech. As a result of the December 2017 deal-making, J&J’s biotech unit (Janssen) will get a global license to commercialize LCAR-B38M in multiple myeloma.
Japanese drugmaker Otsuka Holdings acquired a 10% (1 billion yen) stake in Megakaryon, a venture that creates platelets out of induced pluripotent stem cells in December 2017.
Amgen Ventures participated in Fortuna Fix’s USD $25 million Series B financing in November 2017. Fortuna fix is using its direct reprogramming technology to repair neural tissue.
Astellas Pharma funded a development program with Universal Cells to utilize its Universal Donor Cell Technology in October 2017.
Gilead Sciences acquired Kite Pharma in August 2017 for $11.9B, thereby securing access to Kit’es lead CAR T therapy candidate, Yescarta (Axicabtagene Ciloleucel), which was approved by the FDA in October 2017.
Hitachi Chemical bought PCT cell therapy, a cell therapy CDMO, in May 2017.
FUJIFILM purchased a 10% equity stake in January 2017 in Cynata Therapeutics, the company responsible for the world’s first clinical trial worldwide involving an allogeneic iPSC-derived therapeutic product (CYP-001).
Bayer AG spun off BlueRock Therapeutics with funding of $225 million in December 2016.
Mallinckrodt Pharmaceuticals acquired Stratatech Corporation in August 2016.
JCR Pharmaceuticals Co. Ltd. and Mesoblast in December 3, 2015.
AMAG Pharmaceuticals bought Cord Blood Registry for $700 million in June of 2015. CBR is the largest umbilical cord blood bank in the U.S with 700K+ cord blood and tissue units in storage.
Celgene took a $45 million minority stake in Mesoblast in April 2015. Mesoblast is an Australian-based regenerative medicine company that is a leader in MSC therapeutics.
Novartis has an equity stake in Gamida Cell Ltd. Specifically, Novartis invested $35 million in 2014, $5 million in 2015, and has previously talked about buying Gamida Cell for $600 million.
FUJIFILM bought Cellular Dynamics International (CDI), the world’s leading iPSC company, for $307 million in April 2015.
Johnson & Johnson bet $12.5 million on Capricor Therapeutics cell therapy program for cardiovascular applications (CAP-1002) through its subsidiary, Janssen Pharmaceuticals, in January 2014.
PerkinElmer bought ViaCord for $300 million in October 2007. ViaCord is the 2nd largest an umbilical cord blood bank in the U.S.
Teva Pharmaceuticals entered a joint venture (JV) with Gamida Cell Ltd (2005).
Much of this partnering activity has been supported by accelerated regulatory pathways that have been passed in major healthcare markets worldwide, including the U.S., Japan, and South Korea. In Japan, the government passed the “Act on the Safety on Regenerative Medicine” and making revisions to the “Pharmaceutical and Medical device Act” in late 2014, giving a major boost to cell therapy development within Asia. Additionally, the EU has a program for product acceleration – the Adaptive Pathways.

Want to learn more? View the “Regenerative Medicine Industry Database 2018? featuring 600+ companies worldwide.

Huil maar niet 15 januari 2018 10:47

www.fmfvacatures.nl/vacs/showvac.php?...

www.fmfvacatures.nl/vacs/showvac.php?...

Kogovus 15 januari 2018 11:43

quote:
Huil maar niet schreef op 15 januari 2018 10:47:
www.fmfvacatures.nl/vacs/showvac.php?...

www.fmfvacatures.nl/vacs/showvac.php?...

Hmmmmm, lijkt mij niet dat je personeel aanneemt als er geen noodzaak voor is, toch?

Koro 15 januari 2018 11:56

Kiadis wordt niet overgenomen! Kiadis gaat echt voor de 100euro!!!

[verwijderd] 15 januari 2018 12:11

Begin van een mooie week?
Volume neemt toe, koers +4%

[verwijderd] 15 januari 2018 12:12

Lang genoeg op 8 gestaan op naar de 9

[verwijderd] 15 januari 2018 12:20

De trein is vertrokken

[verwijderd] 15 januari 2018 12:21

Mij benieuwen of deze dieseltrein echt los mag nu.

[verwijderd] 15 januari 2018 12:30

Da's leuk terugkomen van lunch. Mooie uitbraak met mooi volume.

Windkracht 15 januari 2018 12:31

Zie mijn bericht van afgelopen vrijdag 13.51:
"Het patroon vandaag is wat onrustig......ik verwacht dat we een dezer dagen de bandbreedte gaan verlaten en net als diverse andere biotechs de weg omhoog gaan inslaan. Eigenlijk verwacht ik dit al einde van deze middag dan wel volgende week. Kan het niet onderbouwen, maar baseer dat op het onrustige patroon in het orderboek. We will see"

Het was al erg onrustig de afgelopen dagen.

[verwijderd] 15 januari 2018 12:51

hopelijk kunnen we blijvend stijgen, desnoods rustig... want vaak zijn we de mooie winst kwijt bij slotkoers.
wel iets nieuws op tocht precies want is lang geleden dat we de 8 verlaten. hopelijk voor goed.
nu al +9%, mooi.

iemand nieuws?

1.753 Posts, Pagina: « 1 2 3 4 5 6 ... 12 13 14 15 16 17 18 19 20 21 22 ... 84 85 86 87 88 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 921,94 +2,94 +0,32% 31 jan


Germany40^	21.635,70	-0,42%
BEL 20	4.326,05	-0,06%
Europe50^	5.261,76	-0,47%
US30^	44.557,60	0,00%
Nasd100^	21.475,10	0,00%
US500^	6.040,86	0,00%
Japan225^	39.336,60	0,00%
Gold spot	2.799,05	0,00%
EUR/USD	1,0365	-0,22%
WTI	73,10	0,00%